- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01743365
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)
A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of Cisplatin,5-Fluorouracil(5FU) and Afatinib as first-line therapy in patients with advanced gastric or gastroesophageal junction cancer. The study will include 55 patients in all. The patients will receive open-label Cisplatin intravenous 75mg/m2 on Day 1, 5FU 750mg/m2 at 24-hour intravenous infusion on Days 1-4, and Afatinib 40mg per os on Days 3-5, 8-12, 15-19.
The administration of Afatinib will start on Day 3 of each therapy cycle with an administration interval on each weekend ("Weekday on, Weekend off") for 21 days. Instructions are given on the dose reduction scheme in the presence of toxicity. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 treatment cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule. Imaging will be applied once every 8 weeks, and once every 12 weeks in the Afatinib maintenance therapy phase.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11528
- Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra"
-
Athens, Greece, 14564
- 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
-
Athens, Greece, 14564
- 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
-
Athens, Greece, 15123
- 3rd Dept of Medical Oncology, Hygeia Hospital
-
Athens, Greece, 18547
- 1st Dept of Medical Oncology, Metropolitan Hospital
-
Athens, Greece, 18547
- 2nd Dept of Medical Oncology, Metropolitan Hospital
-
Athens, Greece, 11522
- 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital
-
Athens, Greece, 11527
- 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio"
-
Athens, Greece, 11525
- Dept of Medical Oncology, 251 Air Force Hospital
-
Athens, Greece, 12462
- Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attikon"
-
Heraklion, Greece, 71110
- Dept of Medical Oncology, University Hospital of Heraklion
-
Ioannina, Greece, 45110
- Dept of Medical Oncology, Ioannina University Hospital
-
Patras, Greece, 26504
- Division of Oncology, Dept of Internal Medicine, University Hospital of Patras
-
Thessaloniki, Greece, 56429
- Dept of Medical Oncology, Papageorgiou General Hospital
-
Thessaloniki, Greece, 57001
- Dept of Medical Oncology, Thermi Clinic S.A
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histological or cytological diagnosis of gastric and/or gastroesophageal junction adenocarcinoma/carcinoma.
- Locally advanced or metastatic inoperable disease.
- Life expectancy ≥12 weeks.
- Patients who may have undergone any type of palliative treatment for localised disease, including surgical approaches and palliative radiotherapy, but not in the last four weeks before the trial.
- Adequate bone marrow, hepatic and renal functional reserves (ANC≥1500mm3, PLT≥100mm3, GFR≥50ml/min by Gault Formula, bilirubin <1.5x, Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) <2.5x upper normal limit or 5x in the presence of hepatic metastases).
- Patients must be able to swallow pharmaceutical tablets and to be eligible to receive intravenous chemotherapy.
- Men or women patients must be at least 18 years old.
- Performance Status Scale 0 or 1 (ECOG).
- Measurable disease according to RECIST 1.1.
- Left ventricular ejection fraction (LVEF) ≥50% (ECHO or MUGA).
- Provision of patient informed consent for participation in the study and for the use of biological material for research purposes.
- Willingness and ability to comply with scheduled medical visits, therapeutic treatment programmes, laboratory testing and other study procedures.
Exclusion Criteria:
- Previous systemic first-line therapy.
- Previous therapy with EGFR/HER Tyrosine Kinase Inhibitor (TKI) or other experimental agent.
- Diagnosis of a second malignancy, except basal cell carcinoma of the squamous epithelium or in situ carcinoma of any organ, for which an appropriate treatment has been administered without indications of relapse for 12 months.
- Presence of uncontrolled, active brain metastases (controlled brain metastases are considered those that have been irradiated and have remained stable for at least 4 weeks after radiation therapy).
- Diagnosis of spinal cord compression or carcinomatous meningitis.
- Any of the following that has occurred within 12 months before the start of the study treatment: myocardial infarction, serious or unstable angina pectoris, aortic-coronary or peripheral bypass surgery, symptomatic heart failure, vascular stroke, or transient ischemic attack, or pulmonary embolism.
- Continuing grade ≥2 heart rate abnormalities; atrial fibrillation of any grade.
- Hypertension uncontrolled by medication treatment (>150/100 mm/Hg despite the administration of best medical therapy).
- In the case of previous irradiation of locally advanced disease, absence of measurable tumor sites outside the irradiation field.
- Presence of any other disease which in the opinion of the doctor responsible constitutes a contraindication for the administration of cisplatin, 5FU or afatinib.
- Diagnosed human immunodeficiency virus (HIV) or disease associated with Acquired Immunodeficiency Syndrome (AIDS).
- Pregnancy or lactation. Female patients must be surgically sterilised, menopausal, or must consent to use effective contraception throughout the course of the trial.All female patients with reproduction ability must undergo a pregnancy test (serum or urine). The effective contraceptive technique will be determined by the main investigator or a person authorized by the investigator.
- Any other serious, acute or chronic, medical or psychiatric condition or laboratory analysis finding which, in the investigator's opinion, could create excessive danger as regards the patient's participation in the trial or administration of the trial medication may render a patient ineligible for inclusion in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cisplatin-5FU-Afatinib
Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle.
Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend ("Weekday on, Weekend off") for 21 days.
The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent.
At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Time Frame: At an average of 6 months for each patient
|
Imaging will be performed once every 8 weeks during treatment with cisplatin-5FU-afatinib (6 cycles), and once every 12 weeks in the Afatinib maintenance therapy phase.
|
At an average of 6 months for each patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Overall Survival (OS)
Time Frame: OS will be calculated from the date of treatment initiation to the date of death from any cause assessed up to 36 months.
|
OS will be calculated from the date of treatment initiation to the date of death from any cause assessed up to 36 months.
|
|
Evaluation of Progression-Free Survival (PFS)
Time Frame: PFS will be calculated from the date of treatment initiation to the date of disease progression or date of death, assessed up to 36 months.
|
PFS will be calculated from the date of treatment initiation to the date of disease progression or date of death, assessed up to 36 months.
|
|
Assessment of safety and tolerability
Time Frame: Assessed up to 36 months
|
Distribution of Adverse Events (AEs) according to severity grade. Evaluation of AEs will be performed: On Day 1 and day 10 in cycle 1,on Day 1 in cycles 2-6 (every 21 days) and on Day 1 during maintenance treatment with afatinib (every 4 weeks). |
Assessed up to 36 months
|
Value of prognostic and/or predictive biomarkers measured in tissue and blood samples
Time Frame: Tumor blocks and blood samples will be collected at baseline
|
Immunochemical expression of proteins/messenger ribonucleic acid (mRNA) of the tumor that can be linked to the efficacy / safety of the treatment, the tumor angiogenesis and the mechanism of action of the combination cisplatin/5FU/Afatinib. In bioptic material for gastric or gastroesophageal adenocarcinoma:
In peripheral blood and plasma:HER2 shed extracellular domain (ECD) There may be additions to the biomarkers to be analysed, dependent on the clinical and bibliographical data. |
Tumor blocks and blood samples will be collected at baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: George Pentheroudakis, Ass.Prof, Dept of Medical Oncology, Ioannina University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Cisplatin
- Afatinib
Other Study ID Numbers
- HE7/12
- 2011-006198-25 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Cisplatin-5FU-Afatinib
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminatedA Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell CarcinomaCarcinoma, Squamous Cell | Esophageal NeoplasmsJapan
-
AmgenTakedaCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastric CancerSwitzerland, Italy
-
Groupe Oncologie Radiotherapie Tete et CouCompleted
-
Samsung Medical CenterUnknownEsophageal Squamous Cell CarcinomaKorea, Republic of
-
Rabin Medical CenterDavidoff Cancer CenterUnknown
-
Hospital Alemão Oswaldo CruzRecruitingRectal Cancer | ConsolidationBrazil, Argentina, Uruguay
-
Boehringer IngelheimCompleted
-
Centre Leon BerardBoehringer IngelheimCompletedHead and Neck Squamous Cell CarcinomaFrance
-
Boehringer IngelheimCompleted